msaf79
liked
$The Honest (HNST.US)$
The Honest Company Reports Strong Third Quarter 2024 Results and Raises Full Year Outlook
The Honest Company (NASDAQ: HNST)reported strong Q3 2024 results with record revenue of $99 million, up 15.2% year-over-year. The company achieved positive net income of $165,000, an $8 million improvement from last year's loss. Gross margin expanded significantly by 710 basis points to 38.7%. Operating expenses increased by $3 million to $38 million. The company maintained a st...
The Honest Company Reports Strong Third Quarter 2024 Results and Raises Full Year Outlook
The Honest Company (NASDAQ: HNST)reported strong Q3 2024 results with record revenue of $99 million, up 15.2% year-over-year. The company achieved positive net income of $165,000, an $8 million improvement from last year's loss. Gross margin expanded significantly by 710 basis points to 38.7%. Operating expenses increased by $3 million to $38 million. The company maintained a st...
3
1
msaf79
reacted to
$Agrify (AGFY.US)$
Agrify Secures Financing From Green Thumb Industries and Announces New Leadership
Agrify (AGFY) has secured a $20 million convertible secured note from a Green Thumb Industries subsidiary, with $10M available at closing. Green Thumb also acquired an ownership stake in Agrify through stock and warrant purchases from outgoing executives. Benjamin Kovler, Green Thumb's Founder and CEO, has been appointed as Agrify's Chairman and Interim CEO, replacing Raymond Chang. Additional...
Agrify Secures Financing From Green Thumb Industries and Announces New Leadership
Agrify (AGFY) has secured a $20 million convertible secured note from a Green Thumb Industries subsidiary, with $10M available at closing. Green Thumb also acquired an ownership stake in Agrify through stock and warrant purchases from outgoing executives. Benjamin Kovler, Green Thumb's Founder and CEO, has been appointed as Agrify's Chairman and Interim CEO, replacing Raymond Chang. Additional...
2
msaf79
liked
$Monopar Therapeutics (MNPR.US)$
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
Monopar Therapeutics (Nasdaq: MNPR) has secured an exclusive worldwide license from Alexion, AstraZeneca Rare Disease for ALXN-1840, a Wilson disease drug candidate that completed Phase 3 trials meeting its primary endpoint. The agreement involves an upfront payment combining cash and Monopar equity, plus future tiered royalties and milestone payme...
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
Monopar Therapeutics (Nasdaq: MNPR) has secured an exclusive worldwide license from Alexion, AstraZeneca Rare Disease for ALXN-1840, a Wilson disease drug candidate that completed Phase 3 trials meeting its primary endpoint. The agreement involves an upfront payment combining cash and Monopar equity, plus future tiered royalties and milestone payme...
2
1